Abstract
The introduction of ultrasound (US) microbubble contrast agents has dramatically expanded the possibilities for US detection of prostate cancer. Recent advances in US technology have increased the value of US contrast agents. Many newer US techniques, which are quite sensitive for detection of microbubbles, are yet to be explored for prostate applications. A critical evaluation of the current status of transrectal US imaging for the detection of prostate cancer and background information for US contrast agents and imaging techniques are presented. Early results have demonstrated the feasibility of US contrast agents to enhance US imaging of prostatic disease. The application of US contrast agents for the detection and clinical staging of prostate cancer is promising. Future clinical trials are needed to determine whether the promise of contrast-enhanced US of the prostate will evolve into widespread clinical application.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
